Stock listing

KRX:302440 SK bioscience Co.,Ltd. (SK바이오사이언스) 주가

Follow SK bioscience Co.,Ltd. into a list and get an email when it puts out news.

Share price · KRX:302440

₩38,500 KRW +300 (+0.8%)

Close on Nov 20, 2026

Past year -26.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩37,400 – ₩39,050 KRWNov 20, 2026
Volume
77,747 sharesNov 20, 2026
Market cap
₩3.02T KRWAt the close on Nov 20, 2026 · price × 78.46M shares outstanding
52-week range
₩31,500 – ₩55,700 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩3.25B KRWMedian day 73,352 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
SK bioscience Co.,Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:302440 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩38,500+300+0.8%₩37,550₩39,050₩37,40077,747
₩38,200-1,700-4.3%₩39,450₩40,100₩38,20098,969
₩39,900+600+1.5%₩39,500₩41,450₩39,250127,589
₩39,300+300+0.8%₩39,250₩40,250₩38,80054,627
₩39,000-450-1.1%₩38,800₩40,050₩38,80065,093
₩39,450-500-1.3%₩39,900₩40,400₩38,450114,498
₩39,950+250+0.6%₩39,800₩41,550₩39,350107,143
₩39,700-700-1.7%₩39,950₩41,700₩39,000138,359
₩40,400+2,000+5.2%₩38,250₩42,950₩38,200510,374
₩38,400+1,450+3.9%₩35,450₩39,700₩35,200204,513
₩36,950+2,450+7.1%₩35,200₩37,300₩35,200135,104
₩34,500+1,300+3.9%₩33,250₩34,500₩32,85098,043
₩33,200-50-0.2%₩33,400₩33,450₩32,100174,588
₩33,250+500+1.5%₩32,300₩33,700₩32,20044,185
₩32,750+550+1.7%₩32,500₩33,250₩31,85087,076
₩32,200+50+0.2%₩32,150₩32,550₩31,55055,704
₩32,150+400+1.3%₩32,000₩32,750₩32,00065,710
₩31,750-250-0.8%₩32,150₩32,700₩31,70073,074
₩32,000-1,150-3.5%₩32,800₩33,150₩31,50094,907
₩33,150-1,450-4.2%₩34,400₩34,900₩33,00081,409
₩34,600-850-2.4%₩35,350₩35,600₩34,55054,112
₩35,450-350-1.0%₩36,150₩36,750₩35,40072,210
₩35,800-1,200-3.2%₩36,500₩37,550₩35,65059,676
₩37,000+700+1.9%₩36,200₩37,150₩35,65075,544
₩36,300+950+2.7%₩35,250₩37,250₩35,20083,722
₩35,350-950-2.6%₩36,100₩36,150₩34,80083,971
₩36,300-150-0.4%₩36,550₩36,950₩35,70058,189
₩36,45000.0%₩35,600₩36,500₩34,75097,339
₩36,450-300-0.8%₩36,850₩37,450₩36,15069,609
₩36,750-1,250-3.3%₩37,450₩37,500₩36,75087,838
₩38,000+750+2.0%₩38,250₩38,750₩37,50082,432
₩37,250+750+2.1%₩36,700₩37,800₩36,65066,392
₩36,500-300-0.8%₩37,100₩37,150₩36,05046,272
₩36,800+700+1.9%₩36,400₩37,200₩36,15062,553
₩36,100+200+0.6%₩36,100₩36,450₩35,55048,212
₩35,900-550-1.5%₩36,400₩36,400₩35,45049,953
₩36,450+700+2.0%₩35,750₩36,850₩35,50068,610
₩35,75000.0%₩35,550₩36,100₩35,45059,220
₩35,750+100+0.3%₩35,800₩36,150₩35,50051,840
₩35,650+500+1.4%₩35,350₩36,050₩35,20053,334
₩35,150-1,100-3.0%₩36,600₩36,800₩35,150103,032
₩36,250+50+0.1%₩36,400₩36,575₩36,00041,435
₩36,200-550-1.5%₩36,350₩36,800₩35,85055,079
₩36,750-1,050-2.8%₩37,350₩37,800₩36,60063,476
₩37,800+550+1.5%₩36,900₩38,150₩36,85069,063
₩37,250-750-2.0%₩37,000₩37,850₩36,95053,864
₩38,000+700+1.9%₩36,800₩38,000₩36,65097,021
₩37,300+550+1.5%₩36,700₩37,350₩36,40054,490
₩36,750-850-2.3%₩37,800₩38,100₩36,75064,129
₩37,600-300-0.8%₩38,150₩38,150₩37,50065,260
₩37,900+150+0.4%₩38,050₩38,150₩37,65046,060
₩37,750+300+0.8%₩37,500₩39,050₩37,20081,339
₩37,450-900-2.3%₩37,750₩38,200₩37,40073,629
₩38,350-50-0.1%₩38,700₩38,900₩38,00063,567
₩38,400-550-1.4%₩38,450₩38,900₩37,45075,323
₩38,950+500+1.3%₩38,300₩38,950₩38,00057,833
₩38,450+350+0.9%₩37,900₩38,650₩37,75081,128
₩38,100+550+1.5%₩37,900₩38,250₩37,05085,009
₩37,550-750-2.0%₩37,750₩37,800₩36,40087,866
₩38,300+1,800+4.9%₩37,500₩38,500₩37,150106,982
₩36,500-1,250-3.3%₩36,800₩37,000₩35,75073,765
₩37,750+1,950+5.4%₩38,200₩39,150₩37,100183,719
Ticker
KRX:302440
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
KRX
Currency
KRW

What changed lately

Latest news

All SK bioscience Co.,Ltd. news

SK bioscience Co.,Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
5 in the last 12 months · 14 in all · newest Mar 18, 2026 · oldest 2025

Valuation

EV/sales 4.1× against a median of 19.6×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
₩2.72T KRW
P/E
Loss
EV/sales
4.1×
EV/EBITDA
Negative EBITDA
Price/book
1.7×
Gross margin
14.3%
Operating margin
−19.9%
Net margin
−12.8%
Debt to equity
0.3×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
SK bioscience Co.,Ltd. · KRX:302440US$2.26BUS$2.03Bn/a4.1×n/a1.7×−12.8%0.3×n/a
Keymed Biosciences, Inc. · HKEX:2162US$2.43BUS$2.04Bn/a19.6×n/a4.0×−73.0%0.2×n/a
InSilico Medicine Cayman TopCo · HKEX:3696US$2.29BUS$1.70Bn/a30.3×n/a4.2×−626.5%0.0×n/a
Arcus Biosciences, Inc. · NYSE:RCUSUS$2.25BUS$1.72Bn/a17.2×n/a6.3×−453.0%0.3×1.37
NewAmsterdam Pharma Company N.V. · NASDAQ:NAMSUS$2.20BUS$1.57Bn/a60.6×n/a3.5×−789.9%0.0×1.41
Lakefront Biotherapeutics · EURONEXT:LKFTUS$2.20B−US$260.8M3.4×−0.2×n/a0.6×60.2%0.0×n/a
Pharvaris N.V. · NASDAQ:PHVSUS$2.20BUS$1.89Bn/an/an/a7.5×n/a0.0×0.76
BioArctic AB Class B · OMXSTO:BIOA_BUS$2.19BUS$2.00B212×20.4×90.0×11.1×10.5%0.0×n/a
Beam Therapeutics Inc. · NASDAQ:BEAMUS$2.16BUS$1.22Bn/a8.3×n/a2.3×−73.9%0.1×1.90
Celldex Therapeutics, Inc. · NASDAQ:CLDXUS$2.15BUS$1.50Bn/an/an/a3.3×n/a0.0×1.07
Palvella Therapeutics, Inc. · NASDAQ:PVLAUS$2.09BUS$1.85Bn/an/an/a10.6×n/a0.0×1.50
Median of the othersUS$2.20BUS$1.71B108×19.6×90.0×4.1×−73.9%0.0×1.39

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
36200.00 KRW · Analysts' mean
EPS, year to Dec 2026
-829.50 · 1 analyst
Revenue, year to Dec 2026
714.6B · 5 analysts

Events

Next results
Feb 3, 2027 (expected)
QuarterResultsShare move
Quarter to Sep 30, 2026Nov 12, 2026 · Before open−1.3%
Q2 2026Aug 13, 2026 · Before open+1.0%
Q1 2026May 13, 2026 · Before open−1.6%
Q4 2025Mar 13, 2026 · Before open+0.7%
Q3 2025Nov 13, 2025−1.6%
Q2 2025Aug 12, 2025 · Before open−0.7%
Q1 2025May 14, 2025 · Before open+0.5%
Q4 2024Feb 5, 2025 · Before open+2.1%
Q3 2024Nov 13, 2024 · Before open−3.0%
Q2 2024Aug 13, 2024 · Before open−2.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open−0.7%
Q4 2023Feb 1, 2024 · Before open+0.9%
Q3 2023Oct 26, 2023 · Before open−1.0%
Q2 2023Jul 28, 2023 · Before open−3.1%
Q1 2023Apr 27, 2023 · Before open−0.8%
Q4 2022Mar 3, 2023 · Before open+5.5%
Q3 2022Nov 14, 2022 · Before open+3.5%
Q2 2022Aug 12, 2022 · Before open+2.4%
Q1 2022May 13, 2022 · Before open+2.1%
Q4 2021Feb 7, 2022 · Before open−2.6%

Open Events

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue651.4B267.5B369.5B456.7B929.0B225.6B183.9B88.2B
Cost of revenue575.4B236.6B227.3B217.1B358.7B130.3B110.9B49.0B
Gross profit75.9B31.0B142.2B239.6B570.3B95.3B79.6B39.2B
Research and development69.9B71.4B85.7B58.0B47.3B26.0B27.7B10.5B
Selling, general and administrative48.2B40.9B25.3B27.3B15.7B12.8B12.6B7.04B
Operating income-123.5B-138.4B-12.0B115.0B474.2B37.7B6.47B15.2B
Depreciation and amortization91.0B49.2B34.8B27.2B18.8B16.5B14.5B6.59B
EBITDA-32.5B-89.2B22.8B142.3B493.0B54.2B21.0B21.8B
Interest expense9.40B3.68B1.40B2.46B3.43B4.15B3.95B2.42B
Income before tax-85.9B-89.1B7.33B141.7B471.1B37.3B18.5B864.0M
Income tax116.0B4.40B
Net income-57.4B-53.9B22.3B122.5B355.1B32.9B14.7B420.8M
Earnings per share, basic-732.13-701.32290.491,594.764,642.34537.41239.836.88

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents105.6B312.7B127.0B225.3B98.0B25.0B14.4B4.49B
Short-term investments800.7B845.4B1.15T1.26T1.55T183.7B80.1B99.2B
Receivables122.0B94.5B12.9B39.6B38.0B30.5B32.2B42.9B
Inventory189.2B211.1B80.6B187.4B135.0B70.3B36.4B31.9B
Current assets1.25T1.58T1.38T1.78T1.84T333.9B170.7B180.7B
Property, plant and equipment221.0B189.5B
Goodwill55.3B57.4B
Total assets2.96T2.84T1.85T2.14T2.11T562.2B404.0B402.7B
Accounts payable35.3B17.8B3.37B11.1B63.8B17.5B18.4B11.1B
Current liabilities326.2B310.6B135.6B380.0B460.0B180.6B45.5B61.8B
Long-term debt464.7B383.3B35.5B102.2B116.6B125.8B
Total liabilities918.3B821.1B148.6B400.2B508.8B298.4B171.2B192.0B
Shareholders' equity1.79T1.80T1.70T1.74T1.60T263.8B232.7B210.7B
Shares outstanding78.4M76.8M76.8M76.8M76.5M61.2M61.2M61.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations102.5B-128.0B29.3B-125.0B536.6B120.2B21.8B14.9B
Capital spending-260.4B-172.2B-50.3B-76.5B-42.9B-9.93B-24.0B-6.31B
Free cash flow-157.9B-300.2B-20.9B-201.4B492.1B110.0B-4.04B8.59B
Cash from investing-1.42T-108.1B
Cash from financing958.4B-1.54B
Change in cash-207.1B185.7B-98.3B127.3B73.1B10.6B9.89B-1.90B

Open Financials

Cap table

Built by 6ix from SK bioscience Co.,Ltd.’s releases

Common shares
78,456,553
Fully diluted
78,456,553

Fully diluted

LineShares
Common shares78,456,553

Share count over time

CountShares
Nov 22, 202678,456,553

Open Cap table

Shareholders

HolderSharesValueAs of
Vanguard Total International Stock Index Fund373KUS$8.75MJul 31, 2026
iShares Core MSCI Emerging Markets ETF278KUS$7.54MMay 31, 2026
Vanguard Developed Markets Index Fund232KUS$5.38MJun 30, 2026
Vanguard Ftse All-World Ex-Us Index Fund57,312US$1.34MJul 31, 2026
Emerging Markets Core Equity 2 Portfolio51,737US$1.21MJul 31, 2026
Schwab International Equity ETF47,767US$1.3MMay 31, 2026
iShares Core MSCI Total International Stock ETF42,401US$995KJul 31, 2026
Vanguard Pacific Stock Index Fund28,401US$666KJul 31, 2026
The Emerging Markets Small Cap Series27,511US$646KJul 31, 2026
Fidelity Total International Index Fund24,246US$562KJul 31, 2026
All 37 holders
HolderSharesValueAs of
Dimensional Emerging Markets Core Equity 2 ETF23,071US$548KJul 31, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF21,897US$505KJun 30, 2026
Dimensional World ex. U.S. Core Equity 2 ETF21,557US$512KJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account21,529US$500KJun 30, 2026
Vanguard Total World Stock Index Fund20,314US$477KJul 31, 2026
Franklin FTSE South Korea ETF18,540US$428KJun 30, 2026
World ex U.S. Core Equity Portfolio6,398US$150KJul 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio6,365US$147KJun 30, 2026
Dimensional Emerging Core Equity Market ETF6,162US$146KJul 31, 2026
iShares MSCI Emerging Markets Small-Cap ETF5,974US$162KMay 31, 2026
Vanguard ESG International Stock ETF4,565US$124KMay 31, 2026
Emerging Markets Social Core Equity Portfolio3,630US$85,187Jul 31, 2026
Avantis Emerging Markets Small Cap Equity ETF2,928US$79,437May 31, 2026
Emerging Markets Sustainability Core 1 Portfolio2,682US$62,940Jul 31, 2026
Emerging Markets ex China Core Equity Portfolio2,523US$59,208Jul 31, 2026
Dimensional Emerging Markets Value ETF1,830US$43,449Jul 31, 2026
Dimensional Emerging Markets Sustainability Core 1 ETF1,561US$37,062Jul 31, 2026
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund1,150US$27,304Jul 31, 2026
Avantis Emerging Markets Equity ETF917US$24,878May 31, 2026
Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF420US$11,399May 29, 2026
Destinations International Equity Fund416US$11,283May 31, 2026
Dimensional Emerging Markets ex China Core Equity ETF398US$9,450Jul 31, 2026
Avantis Emerging Markets ex-China Equity ETF363US$9,848May 31, 2026
Avantis Responsible Emerging Markets Equity ETF159US$4,314May 31, 2026
Franklin FTSE Asia ex Japan ETF112US$2,584Jun 30, 2026
Vanguard Developed Markets Ex-Us Growth Index ETF36US$977May 31, 2026
Vanguard Developed Markets Ex-Us Value Index ETF10US$271May 31, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about SK bioscience Co.,Ltd.